Biotechnology research and development laboratories or services · California

Nektar Therapeutics SFMB

San Francisco, CA · ~300 workers · 5 years of OSHA Injury Tracking Application data.

D
Poor Safety Record
0.6
Avg TCR
0.5
Industry avg
0
Fatalities
Subscribe to safety-record updates (RSS)

The verdict

Nektar Therapeutics SFMB runs at 122% of its industry's injury rate - more dangerous than the typical Biotechnology research and development laboratories or services workplace, earning a grade D.

Nektar Therapeutics SFMB: 0.6 TCR = 122% of Biotechnology research and development laboratories or services BLS 0.5 · 5y Form 300A (see methodology below)

Nektar Therapeutics SFMB safety composite

Nektar Therapeutics SFMB scores strongest on dart rate (safer than 76% of same-industry peers) and weakest on fatalities (safer than 50%), blended into one 0-100 breakdown against same-industry peers. A missing measure drops out and redistributes its weight rather than deflating the score. This is a per-dimension breakdown, distinct from the single letter grade above it (which weights TCR alone against the BLS industry benchmark).

C

63/100

Percentile-weighted across 3 of 3 measures

Total Case Rate (TCR)
C 0.61 per 100 workers

Safer than 59% of industry peers

DART rate
B 0 per 100 workers

Safer than 76% of industry peers

Fatalities
D 0

Safer than 50% of industry peers

Benchmarked live against every credibly-rated employer in the same NAICS industry code in the current OSHA extract (a segment must have at least 8 rated peers to benchmark). Not a legal or compliance determination; PlainSafetyScore's own weighting (TCR 40%, DART 35%, fatalities 25%).

Rising injury rate

Nektar Therapeutics SFMB: 0.7 → 1.2 TCR

Peak year 2023 @ 1.2 TCR · DART/TCR 0× in 2023

Nektar Therapeutics SFMB's TCR rose 0.6 from 0.7 in 2017 to 1.2 in 2023. In 2023, DART was 0× this establishment's average TCR (severity share of cases).

OSHA ITA Form 300A scorecard

Establishment book 541711 · San Francisco, CA ABOVE-IND · MID

Grade D · TCR 0.6 · 122% of ind

  • DART 0.0 DART
  • RANK #17/51
  • PHOTO Syros Pharmaceutical…
  • BOOK 5y book
  • INJ 7 inj
  • SIZE ~300 FTE

Nearest TCR peer: Syros Pharmaceuticals, Inc. (0.0 TCR gap)

Read with this employer → · Industry book → · California employers → · Look up another →

Nektar Therapeutics SFMB in the TCR neighbourhood

Average Total Case Rate among this establishment and nearest same-industry peers

TCR

What this shows Nektar Therapeutics SFMB averages 0.6 TCR (122% of the Biotechnology research and development laboratories or services BLS benchmark).

Source U.S. Department of Labor, OSHA Injury Tracking Application (Form 300A) As of 2026-08-25

Nektar Therapeutics SFMB TCR series: 2017=0.7 · 2018=0.5 · 2020=0.2 · 2022=0.4 · 2023=1.2 · BLS 0.5

Where Nektar Therapeutics SFMB falls in its industry

189 Biotechnology research and dev establishments

Safer than 59% of graded establishments in this industry, whose median TCR is 0.8.

More dangerous than peersSafer than peers

Narrower to California alone (the establishments it most directly competes with for workers and contracts): ranked #17 safest of 51 Biotechnology research and dev employers in California.

Nektar Therapeutics SFMB (300 employees, TCR 0.6) among 29 same-industry peers, split at the industry median of 296 employees and a TCR of 0.8 2×2 strategic matrix plotting 30 entities by Average employees (X) and Total Case Rate (Y), with a crosshair dividing the plot into four quadrants. Larger & higher-riskSmaller & higher-riskLarger & saferSmaller & safer than peers 01,0002,0003,0004,0005,000 05101520 Average employees Total Case Rate Nektar Therapeutics SFMB
Nektar Therapeutics SFMB (300 employees, TCR 0.6) among 29 same-industry peers, split at the industry median of 296 employees and a TCR of 0.8

Nektar Therapeutics SFMB has more employees than the Biotechnology research and development l median and a lower injury rate than the industry's median TCR of 0.8. Workforce size and injury rate do not always move together within the same industry -- some of its smaller peers run higher rates than its larger ones, and vice versa.

Year-by-Year Safety Data

Year TCR DART Injuries Illnesses Fatalities
2023 1.2 0.0 1 0 0
2022 0.4 0.0 1 0 0
2020 0.2 0.2 1 0 0
2018 0.5 0.3 2 0 0
2017 0.7 0.3 2 0 0

OSHA ITA peer cross-reference

Establishment peer ledger

541711 · CA · San Francisco

189 Biotechnology research and development laboratories or services employers nationwide with a credible TCR · 51,834 rated employers in California with headcount on file · 1,144 employers in San Francisco, CA · 4 cross-state NAT-TCR peers · 4 cross-state NAT-SIZE peers. Closest matches by relationship code are listed below.

Rel Establishment Metric
NAICS-TCR Syros Pharmaceuticals, Inc. 0.6 TCR
NAICS-TCR Novartis Institutes for Biomedical Research, Inc 0.6 TCR
NAICS-TCR Fred Hutchinson Cancer Research Center 0.6 TCR
NAICS-TCR Battelle - Crystal City Operations 0.6 TCR
STATE-SIZE Fairbanks Ranch 300 FTE
STATE-SIZE MCF4 Solutions 300 FTE
STATE-SIZE LADWP 14401 SATICOY 300 FTE
STATE-SIZE OAKLAND SERVICE CENTER 300 FTE
CITY-NEAR UC San Francisco 18,070 FTE
CITY-NEAR DoorDash, Inc. 12,430 FTE
CITY-NEAR UC San Francisco Health 12,262 FTE
CITY-NEAR SFO - Airport United Airlines Offices 11,622 FTE
NAT-TCR Entergy Choctaw County Generation Station 0.6 TCR
NAT-TCR BT Irving 0.6 TCR
NAT-TCR Michelin North America US7 0.6 TCR
NAT-TCR NVE, Inc. 0.6 TCR
NAT-SIZE CECO Concrete Construction : Miami 300 FTE
NAT-SIZE BASF Corporation - McIntosh Site 300 FTE
NAT-SIZE Lewisgale Hospital Pulaski 300 FTE
NAT-SIZE KPI,Inc 300 FTE

Rel codes: NAICS-TCR · STATE-SIZE · CITY-NEAR · NAT-TCR/NAT-SIZE cross-state. Read with this employer →

Data Source: OSHA Injury Tracking Application (ITA), mandatory establishment-level injury/illness reports. Grades compare employer Total Case Rate (TCR) to BLS IIF industry benchmarks. Data covers years reported by this establishment: 2023, 2022, 2020, 2018, 2017. This is publicly available government data - not a legal determination of workplace conditions.
Data sourced from official public datasets. See our methodology for details.